RECRUITING
I'm interested ...!!
Carboprost (Hemabate) for Fibroid Resection
The purpose of this research study is to determine if low-dose (i.e., a fraction of what is commonly used) carboprost (Hemabate) helps facilitate fibroid removal (myomectomy).
Conditions:
🦠 Fibroid Uterus 🦠 Gynecologic Disease 🦠 Leiomyoma, Uterine
🗓️ Study Start (Actual) 12 July 2022
🗓️ Primary Completion (Estimated) July 2024
✅ Study Completion (Estimated) July 2024
👥 Enrollment (Estimated) 30
🔬 Study Type INTERVENTIONAL
📊 Phase EARLY_PHASE1
Locations:
📍 Chicago, Illinois, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • * Patients scheduled to undergo myomectomy with a surgeon in the division of Minimally Invasive Gynecologic Surgery
    • * Ability to understand and the willingness to sign a written informed consent

    Exclusion Criteria:

    • * If any oxytocic agents have been or will be administered prior to surgery
    • * History of renal and/or hepatic impairment
    • * Active cardiac disease, pulmonary disease, or pelvic inflammatory disease (PID)
    • * Anemia (Hgb \< 7g/dL), diabetes mellitus, jaundice, or epilepsy
Ages Eligible for Study: 18 Years to N/A (ADULT, OLDER_ADULT)
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: No

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 5 August 2022
  • First Submitted that Met QC Criteria 24 August 2022
  • First Posted 29 August 2022

Study Record Updates

  • Last Update Submitted that Met QC Criteria 2 November 2023
  • Last Update Posted 7 November 2023
  • Last Verified November 2023
I'm interested ...!!